Abivax (ABVX) Change in Working Capital (2024 - 2026)

Abivax's Change in Working Capital history runs 3 years deep, the most recent figure standing at -$53.3 million for Q1 2026.

• On a quarterly basis, Change in Working Capital fell 19.87% year-over-year to -$53.3 million in Q1 2026; TTM through Mar 2026 was -$11.0 million, a 79.35% increase from a year earlier, with the FY2025 full-year figure at -$4.2 million, down 175.94% from the prior year.
• Change in Working Capital fell to -$53.3 million in Q1 2026 per ABVX's latest filing, from $171.9 million in the prior quarter.
• Across five years, Change in Working Capital topped out at $171.9 million in Q4 2025 and bottomed at -$194.9 million in Q3 2025.
• The 3-year median for Change in Working Capital is -$18.3 million (2024), against an average of -$6.7 million.
• Biggest YoY gain for Change in Working Capital was 457.79% in 2025; the steepest drop was 1144.3% in 2025.
• Year by year, Change in Working Capital stood at $124.4 million in 2024, then jumped by 38.19% to $171.9 million in 2025, then plunged by 131.03% to -$53.3 million in 2026.
• Per Business Quant, the three latest ABVX Change in Working Capital figures stand at -$53.3 million (Q1 2026), $171.9 million (Q4 2025), and -$194.9 million (Q3 2025).